Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported a share buy-back of 70,500 H shares on 31 August 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The repurchase, executed on-market, was completed at prices ranging from HKD 16.01 to HKD 16.05 per share, equating to an average cost of approximately HKD 16.03 per share and an aggregate consideration of about HKD 1.13 million. The transaction represents 0.01% of Fosun Pharma’s outstanding H-share capital prior to the buy-back.

Following the transaction, the company’s issued H shares (excluding treasury shares) declined from 540.75 million to 540.68 million. Treasury shares increased to 11.26 million, while the total issued share count remained unchanged at 551.94 million.

The buy-back was executed under the share repurchase mandate approved on 16 June 2026, which authorises the company to repurchase up to 54.10 million shares. Cumulative repurchases under this mandate now total 287,500 shares, equal to 0.05% of the issued share capital on the mandate date. In line with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 30 September 2026.